Alemtuzumab therapy in B-cell lymphoproliferative disorders
- 1 August 2003
- journal article
- review article
- Published by Elsevier in Seminars in Oncology
- Vol. 30 (4) , 493-501
- https://doi.org/10.1016/s0093-7754(03)00253-7
Abstract
No abstract availableKeywords
This publication has 51 references indexed in Scilit:
- Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignanciesBlood, 2003
- Frequency and type of serious infections in fludarabine‐refractory B‐cell chronic lymphocytic leukemia and small lymphocytic lymphomaCancer, 2002
- Chronic B cell malignancies and bone marrow microenvironmentSeminars in Cancer Biology, 2002
- Alemtuzumab in Relapsed or Refractory Chronic Lymphocytic Leukemia and Prolymphocytic LeukemiaLeukemia & Lymphoma, 2002
- CD52 Expression in Mantle Cell LymphomaLeukemia & Lymphoma, 2002
- A Phase II Multicenter Study of CAMPATH-1H Antibody in Previously Treated Patients with Nonbulky Non-Hodgkin's LymphomaLeukemia & Lymphoma, 2001
- In vivo‘Purging’ of residual disease in CLL with Campath‐1HBritish Journal of Haematology, 1997
- Subcutaneous CAMPATH‐1H in fludarabine‐resistant/relapsed chronic lymphocytic and B‐prolymphocytic leukaemiaBritish Journal of Haematology, 1997
- Mechanism of first-dose cytokine-release syndrome by CAMPATH 1-H: involvement of CD16 (FcgammaRIII) and CD11a/CD18 (LFA-1) on NK cells.Journal of Clinical Investigation, 1996
- Immunohistochemical analysis of CDw52 antigen expression in non-Hodgkin's lymphomas.Journal of Clinical Pathology, 1994